Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | CD22 |
Clinical data | |
Trade names | LymphoCide |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
PubChem SID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
(what is this?) (verify) |
Epratuzumab (planned trade name LymphoCide) is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as systemic lupus erythematosus (SLE). [1] [2]
A clinical trial for relapsed adult acute lymphoblastic leukemia (ALL) has reported initial results. [3]
Results have been published for a phase II trial in untreated follicular lymphoma. [3]
Early results from a phase II trial for Diffuse large B-cell lymphoma (DLBCL) were encouraging. [3] [4]
The manufacturers in August 2009 announced success in early trials against SLE,
[5] and started two
Phase III clinical trials.
July 2015 : Both phase III trials (EMBODY1/2) for SLE failed to meet their primary endpoint.
[6]
Epratuzumab binds to the glycoprotein CD22 of mature and malignant B-cells.
Elevated CD22 and other B-cell receptor (BCR) proteins are associated with SLE. "Epratuzumab's mechanism of action transfers these BCR proteins to helper cells called effector cells which reduces B-cell destruction and epratuzumab's impact on the body's immune system" [6] via a process called trogocytosis. [3] Other SLE therapies destroy B-cells which compromises the immune system.
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | CD22 |
Clinical data | |
Trade names | LymphoCide |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
PubChem SID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
(what is this?) (verify) |
Epratuzumab (planned trade name LymphoCide) is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as systemic lupus erythematosus (SLE). [1] [2]
A clinical trial for relapsed adult acute lymphoblastic leukemia (ALL) has reported initial results. [3]
Results have been published for a phase II trial in untreated follicular lymphoma. [3]
Early results from a phase II trial for Diffuse large B-cell lymphoma (DLBCL) were encouraging. [3] [4]
The manufacturers in August 2009 announced success in early trials against SLE,
[5] and started two
Phase III clinical trials.
July 2015 : Both phase III trials (EMBODY1/2) for SLE failed to meet their primary endpoint.
[6]
Epratuzumab binds to the glycoprotein CD22 of mature and malignant B-cells.
Elevated CD22 and other B-cell receptor (BCR) proteins are associated with SLE. "Epratuzumab's mechanism of action transfers these BCR proteins to helper cells called effector cells which reduces B-cell destruction and epratuzumab's impact on the body's immune system" [6] via a process called trogocytosis. [3] Other SLE therapies destroy B-cells which compromises the immune system.